Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06074562 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 405
- Enrollment target
NCT06074562 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 405 participants.
The verdict
NCT06074562, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 405 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.
Interventions
- DRUG Placebo
- DRUG LY3556050
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 405 participants |
| Start Date | 2023-10-05 |
| Est. Completion | 2025-06-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06074562
The ClinicalTrials.gov registry entry for NCT06074562 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 405 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06074562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06074562 about?
NCT06074562 is a clinical study titled "A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain". The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.
What is the current status of trial NCT06074562?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 405 participants. The study started on 2023-10-05. Estimated completion is 2025-06-11.
What interventions are being tested in trial NCT06074562?
The interventions under investigation include: Placebo (DRUG), LY3556050 (DRUG).
Who is sponsoring clinical trial NCT06074562?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.